Euroland - Welcome Page

TimeZone

Currency

Language

HOME

ABOUT US MY EUROLAND USERS’ PAGE CORPORATE SITES CONTACT US SITE OVERVIEW LINKS

Press releases - Corporate Sites

Select Stock Market:

All	Abu Dhabi	Amsterdam	BATS	Bombay	Brussels	Burgundy	Chi-X	Copenhagen	Dubai	Dublin	Frankfurt
Hanoi	Helsinki	HoChiMinh	Hong Kong	Iceland	Lisbon	London	Madrid	Milan	Moscow	Moscow Classica
Nasdaq	NSE (India)	NYSE	NYSE MKT	Oslo	Paris	Riga	Shanghai	Stockholm	Tallinn	Tokyo
Toronto	TSX Venture	Tunis	USOTC	Warsaw	Vienna	Vilnius	XETRA	Zurich

Select Period:						Order by:
All	Today	Yesterday	Last week	Last month		Date	Company

2014-07-03
EISAI CO., LTD. : EISAI RECEIVES EUROPEAN COMMISSION APPROVAL OF INDICATION EXPANSION FOR ANTICANCER AGENT HALAVEN® FOR ADVANCED BREAST CANCER AFTER ONLY ONE PRIOR CHEMOTHERAPY

2014-07-30
EISAI CO., LTD. : EMA GRANTS EISAI’S ANTICANCER AGENT LENVATINIB REQUEST FOR ACCELERATED ASSESSMENT

2014-08-01
EISAI CO., LTD. : EISAI ANNOUNCES PERSONNEL CHANGES FOR ITS CHINESE SUBSIDIARY EISAI CHINA INC. EFFECTIVE AUGUST 1, 2014

2014-08-01
EISAI CO., LTD. : CONTINUATION OF “POLICY FOR PROTECTION OF THE COMPANY'S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)”

2014-08-07
EISAI CO., LTD. : EISAI SUPPORTS EARTHQUAKE RELIEF EFFORTS IN YUNNAN, CHINA

2014-08-08
EISAI CO., LTD. : EISAI ANNOUNCES TOP-LINE PHASE III TRIAL RESULTS OF ERIBULIN IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING AT LEAST TWO PRIOR REGIMENS

2014-08-18
EISAI CO., LTD. : EISAI SUBMITS MARKETING APPROVAL APPLICATIONS FOR ANTICANCER AGENT LENVATINIB SIMULTANEOUSLY IN EUROPE AND U.S.

2014-08-18
EISAI CO., LTD. : EISAI AND ZERIA CONCLUDE LICENSE AGREEMENT CONCERNING A NEW PROTON PUMP INHIBITOR IN JAPAN

2014-08-20
EISAI CO., LTD. : EISAI SUBMITS APPLICATIONS FOR ANTIEPILEPSY AGENT FYCOMPA® SIMULTANEOUSLY IN EUROPE AND U.S. SEEKING INDICATION EXPANSION AS ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES

2014-08-28
EISAI CO., LTD. : EISAI INTRODUCES NEW LIFESTYLE INFORMATION WEBSITE “BreCare Garden” FOR PATIENTS WITH BREAST CANCER

2014-09-03
EISAI CO., LTD. : EISAI'S U.S. SUBSIDIARY EISAI INC. TO DIVEST U.S. RIGHTS FOR ZONEGRAN® TO CONCORDIA PHARMACEUTICALS INC.

2014-09-10
EISAI CO., LTD. : EISAI AND KYORIN ENTER INTO AGREEMENT CONCERNING COMPOUND LIBRARY USE FOR THE DEVELOPMENT OF NEW ANTIBACTERIAL AGENTS

2014-09-17
EISAI CO., LTD. : EISAI TO PRESENT LATEST CLINICAL DATA ON HALAVEN® (ERIBULIN) AND LENVATINIB AT 39TH ESMO CONGRESS

2014-09-16
EISAI CO., LTD. : EISAI ENTERS TWO JOINT RESEARCH AGREEMENTS TO DEVELOP NEW ANTIMALARIAL MEDICINES

2014-09-16
EISAI CO., LTD. : EISAI ENTERS TWO JOINT RESEARCH AGREEMENTS TO DEVELOP NEW ANTIMALARIAL MEDICINES

2014-09-16
EISAI CO., LTD. : EISAI ENTERS TWO JOINT RESEARCH AGREEMENTS TO DEVELOP NEW ANTIMALARIAL MEDICINES

2014-09-19
EISAI CO., LTD. : EISAI SELECTED SUCCESSIVELY FOR MEMBERSHIP OF DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2014

2014-09-19
EISAI CO., LTD. : ARICEPT® APPROVED IN JAPAN AS TREATMENT FOR DEMENTIA WITH LEWY BODIES

2014-09-26
EISAI CO., LTD. : EISAI SUBMITS APPLICATION IN JAPAN FOR INDICATION EXPANSION OF VASCULAR EMBOLIZATION DEVICE DC BEAD® TO INCLUDE TREATMENT OF HYPERVASCULARIZED TUMORS AND ARTERIOVENOUS MALFORMATIONS

2014-09-30
EISAI CO., LTD. : PHASE III TRIAL OF ARICEPT® IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE IN CHINA MEETS PRIMARY ENDPOINT

20	40	60	80	100	120	140	160	180	200	220	240	260	280	300	320	340	360	380	400
420

2014

Back